Our services are centred around intellectual property that can be registered. We protect innovation, design, and branding across all sectors of industry, and at all stages in the supply chain.

For each IP right we offer services covering strategic advice, pre-registration searches, registrations and renewals, oppositions and dispute resolution. We handle work throughout the world, working with local colleagues in over 100 countries.


Our attorneys specialise in one or more sectors of industry, which enables them to provide quality advice with a commercial focus.

Our patent specialists have detailed understanding of the background technology, which ensures that your patent applications are prepared with the correct scope, reducing the likelihood of challenges from third parties and objections from the patent office.

They also advise whether other forms of protection would be more appropriate. Our brand specialists work with brand managers for leading brands and their advice is commercially focussed making sure that you get the best value from your budget.

New pills instead of windmills – European Medicine Agency to relocate to Amsterdam

21st Nov 2017

The prestigious European Medicine Agency (EMA) is to relocate from London to Amsterdam because of Brexit.

The EMA is responsible for the scientific evaluation of medicines in the EU. EMA’s purpose is to provide independent recommendations on medicines for human and veterinary use, based on a comprehensive scientific evaluation of data. Its activities include assessing whether to provide marketing approval for new medicines in the EU, and monitoring safety of medicines across their lifetime. EMA therefore has a key role in giving patients in the EU access to new medicine.

EMA is presently located in Canary Wharf, London, and there was fierce competition from 18 EU cities, including Copenhagen and Milan, to host EMA following Brexit. On 20th November 2017, 27 of the EU foreign affairs ministers decided to award the prize to Amsterdam.

It is planned that the move will take place by 30 March 2019. It will be interesting to see if there is much disruption to ongoing drug trials or disruption caused by staff losses associated with the move.

This article is for general information only. Its content is not a statement of the law on any subject and does not constitute advice. Please contact Reddie & Grose LLP for advice before taking any action in reliance on it.

Phil Bates
About the author

Would you like to know more? You can talk to Phil Bates who will be able to help. Call +44 (0)20 7242 0901


Register for notifications
Enter your email address here to receive our monthly bulletin of IP news and developments.
    Please read our privacy notice.
Saved Staff
Staff member

Remove all

Saved profiles
Call +44 (0)20 7242 0901
Call +44 (0)1223 360 350
Call +49 (0) 89 206054 267
Call +(00) 31 70 800 2162